| First Author | Sale S | Year | 2006 |
| Journal | Invest New Drugs | Volume | 24 |
| Issue | 6 | Pages | 459-64 |
| PubMed ID | 16505954 | Mgi Jnum | J:117541 |
| Mgi Id | MGI:3696693 | Doi | 10.1007/s10637-006-5947-0 |
| Citation | Sale S, et al. (2006) Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse. Invest New Drugs 24(6):459-64 |
| abstractText | DMU-135 (3,4-Methylenedioxy-3',4',5'-trimethoxy chalcone) is a novel anticancer prodrug designed to be activated into a potent tyrosine kinase inhibitor by the tumour selective enzyme activity of the cytochrome P450 enzyme CYP1B1. CYP1B1 is selectively expressed in a wide variety of tumours including colon. The hypothesis was tested that DMU-135 would inhibit Apc(Min/+) mouse gastrointestinal adenoma formation. From 4-18 weeks of age animals received DMU-135 (0.2% w:w) in AIN93G diet. DMU-135 was well tolerated, induced no systemic side-effects and reduced adenoma multiplicity by 46 +/- 18.3% compared to controls (p < 0.001). Further characterisation of this promising chemopreventive agent is required. |
